Sanofi (NASDAQ: SNY) announced a leadership transition, with Paul Hudson stepping down as Chief Executive Officer on February 17, 2026, and Belén Garijo appointed as his successor, effective April 29, 2026. The Spanish-born executive, currently CEO of Merck KGaA and first woman to lead a DAX40 company, will return to Sanofi—where she previously spent 15 years—with a mandate to strengthen R&D productivity, governance, and innovation capacity.
Forward‑Looking Statements This brief contains forward‑looking statements regarding Sanofi’s leadership transition execution, Belén Garijo’s strategic priorities, and R&D productivity improvements. Actual results may differ due to executive transition risks, cultural integration challenges, and competitive dynamics in Sanofi’s core therapeutic areas.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
